日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

基于模型的纳武利尤单抗和瑞拉利单抗新型固定剂量组合在成人和青少年实体瘤患者中的临床药理学特征

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-2396
Zhao, Yue; Hu, Zheyi; Bathena, Sai Praneeth; Keidel, Sarah; Miller-Moslin, Karen; Statkevich, Paul; Bello, Akintunde; Roy, Amit; Suryawanshi, Satyendra
发表日期：2024
文献求助 收藏

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

贝培加地白介素联合纳武利尤单抗治疗未经治疗的晚期黑色素瘤：开放标签、III期PIVOT IO 001试验结果

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.23.00172
Diab, Adi; Gogas, Helen; Sandhu, Shahneen; Long, Georgina V; Ascierto, Paolo A; Larkin, James; Sznol, Mario; Franke, Fabio; Ciuleanu, Tudor E; Pereira, Caio; Muñoz Couselo, Eva; Bronzon Damian, Fernanda; Schenker, Michael; Perfetti, Aldo; Lebbe, Celeste; Quéreux, Gaëlle; Meier, Friedegund; Curti, Brendan D; Rojas, Carlos; Arriaga, Yull; Yang, Haisu; Zhou, Ming; Ravimohan, Shruthi; Statkevich, Paul; Tagliaferri, Mary A; Khushalani, Nikhil I
黑色素瘤
发表日期：2023
文献求助 收藏

Biodiversity of aquatic organisms in the Mekong Delta, Vietnam

越南湄公河三角洲水生生物多样性

期刊:Biodiversity Data Journal
影响因子:1.1
doi:10.3897/BDJ.11.e105314
Seleznev, Dmitriy G; Dinh, Cu Nguyen; Hai, Truong Ba; Karpova, Evgeniia P; Kim Chi, Duong Thi; Kosolapov, Dmitriy B; Kosolapova, Natalya G; Malin, Mikhail I; Malina, Inga P; Man, Le Quang; Prokin, Alexander A; Prusova, Irina Yu; Sharov, Andrey N; Statkevich, Svetlana V; Tsvetkov, Alexander I; Udodenko, Yuriy G; Zakonnov, Viktor V; Zhdanova, Svetlana M; Krylov, Alexander V; Tiunov, Alexei V
发表日期：2023
文献求助 收藏

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

伊匹木单抗联合纳武利尤单抗治疗晚期实体瘤患者的群体药代动力学

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12477
Sanghavi, Kinjal; Zhang, Jason; Zhao, Xiaochen; Feng, Yan; Statkevich, Paul; Sheng, Jennifer; Roy, Amit; Vezina, Heather E
发表日期：2020
文献求助 收藏

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

晚期恶性肿瘤患者接受纳武利尤单抗联合伊匹木单抗治疗的群体药代动力学研究

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12476
Zhang, Jason; Sanghavi, Kinjal; Shen, Jun; Zhao, Xiaochen; Feng, Yan; Statkevich, Paul; Sheng, Jennifer; Roy, Amit; Zhu, Li
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

一项针对晚期恶性肿瘤患者的I期安全性、药代动力学和药效学研究，评估每三周给药一次的细胞周期蛋白依赖性激酶抑制剂dinaciclib的疗效。

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2017.288
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L; Poon, Jennifer; Small, Karen A; Jou, Ying-Ming; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Statkevich, Paul; Sankhala, Kamelesh K; Sarantopoulos, John; Cleary, James M; Chirieac, Lucian R; Rodig, Scott J; Bannerji, Rajat; Shapiro, Geoffrey I
信号转导
细胞生物学
肿瘤
肿瘤免疫
发表日期：2017
文献求助 收藏

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

一项首次人体试验的 I 期剂量递增研究，评估了新型细胞周期蛋白依赖性激酶抑制剂 dinaciclib 每周一次给药治疗晚期恶性肿瘤患者的疗效。

期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/1479-5876-11-259
Nemunaitis, John J; Small, Karen A; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Jou, Ying-Ming; Statkevich, Paul; Yao, Siu-Long; Bannerji, Rajat
信号转导
细胞生物学
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer

一项针对晚期癌症患者的I期多中心研究，旨在评估持续口服lonafarnib（SCH 66336）联合静脉注射吉西他滨的疗效。

期刊:Cancer Investigation
影响因子:1.9
doi:10.3109/07357907.2011.621912
Wong, Nan Soon; Meadows, Kellen L; Rosen, Lee S; Adjei, Alex A; Kaufmann, Scott H; Morse, Michael A; Petros, William P; Zhu, Yali; Statkevich, Paul; Cutler, David L; Meyers, Michael L; Hurwitz, Herbert I
肿瘤
肿瘤免疫
发表日期：2011
文献求助 收藏

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

评估口服与静脉注射替莫唑胺的暴露等效性

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-009-1078-6
Diez, Blanca D; Statkevich, Paul; Zhu, Yali; Abutarif, Malaz A; Xuan, Fengjuan; Kantesaria, Bhavna; Cutler, David; Cantillon, Marc; Schwarz, Max; Pallotta, Maria Guadalupe; Ottaviano, Fabio H
发表日期：2010
文献求助 收藏